File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

TitleHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
Authors
KeywordsAntiviral Therapy
Hepatitis B Virus
Nucleos(T)Ide Analogue
Issue Date2012
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
Citation
Clinical Gastroenterology And Hepatology, 2012 How to Cite?
Abstract
There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute.
Persistent Identifierhttp://hdl.handle.net/10722/163490
ISSN
2013 Impact Factor: 6.534
ISI Accession Number ID

 

Author Affiliations
  1. The Catholic University of Korea
  2. UCI Medical Center
  3. University of Calgary
  4. University of Hawaii at Manoa
  5. Bristol-Myers Squibb
  6. Mount Sinai School of Medicine
  7. Queen Mary Hospital Hong Kong
  8. National Cheng Kung University
  9. University of California, Los Angeles
  10. Virginia Mason Medical Center
DC FieldValueLanguage
dc.contributor.authorPan, CQen_US
dc.contributor.authorTong, Men_US
dc.contributor.authorKowdley, KVen_US
dc.contributor.authorHu, Ken_US
dc.contributor.authorChang, Ten_US
dc.contributor.authorLai, Cen_US
dc.contributor.authorYoon, SKen_US
dc.contributor.authorLee, SSen_US
dc.contributor.authorCohen, Den_US
dc.contributor.authorTang, Hen_US
dc.contributor.authorTsai, Nen_US
dc.date.accessioned2012-09-05T05:32:07Z-
dc.date.available2012-09-05T05:32:07Z-
dc.date.issued2012en_US
dc.identifier.citationClinical Gastroenterology And Hepatology, 2012en_US
dc.identifier.issn1542-3565en_US
dc.identifier.urihttp://hdl.handle.net/10722/163490-
dc.description.abstractThere are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cghen_US
dc.relation.ispartofClinical Gastroenterology and Hepatologyen_US
dc.subjectAntiviral Therapyen_US
dc.subjectHepatitis B Virusen_US
dc.subjectNucleos(T)Ide Analogueen_US
dc.titleHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailLai, C:hrmelcl@hku.hken_US
dc.identifier.authorityLai, C=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.cgh.2012.03.016en_US
dc.identifier.pmid22475742-
dc.identifier.scopuseid_2-s2.0-84865319280en_US
dc.identifier.hkuros208887-
dc.identifier.isiWOS:000308578400020-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridPan, CQ=8431195300en_US
dc.identifier.scopusauthoridTong, M=7202033792en_US
dc.identifier.scopusauthoridKowdley, KV=26643305700en_US
dc.identifier.scopusauthoridHu, K=55213827000en_US
dc.identifier.scopusauthoridChang, T=7404725147en_US
dc.identifier.scopusauthoridLai, C=7403086396en_US
dc.identifier.scopusauthoridYoon, SK=7404036291en_US
dc.identifier.scopusauthoridLee, SS=7601405566en_US
dc.identifier.scopusauthoridCohen, D=35475416000en_US
dc.identifier.scopusauthoridTang, H=55214347700en_US
dc.identifier.scopusauthoridTsai, N=7006824415en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats